Barrigen is a pre-clinical stage pharmaceutical company with core competency in viral vector development aiming at cancer treatment. Our mission is to improve cancer treatment by deepening the comprehensive understanding of knowledge of immunology, oncology, and virology. To achieve this vision, we’ve taken the full advantages of technologies from rapidly evolved scientific researches. We possess an experienced team of scientists with diverse backgrounds of biological and biomedical sciences including but not limited to oncology, immunology, virology, biotechnology, clinical medicine. We’ve devoted our time and talent largely not only to the internal research of the basic science and mechanisms that underline the immuno-oncology, but also to the research and development for optimization of our lead oncolytic virotherapy candidates. Combining the accumulating knowledge and our advancing technologies, Barrigen continues developing the best-in-class immunotherapies for patients world-wide.